Evidence map›Paper›PMID 29411260›Full record

ArticleInternational ophthalmology2019

A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.

Hande Celiker, Ebru Toker, Isik Kaygusuz Atagunduz

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hande CelikerDepartment of Ophthalmology, Marmara University School of Medicine, Istanbul, Turkey. drhandeceliker@yahoo.com.ORCID http://orcid.org/0000-0002-1683-0725
Ebru TokerDepartment of Ophthalmology, Marmara University School of Medicine, Istanbul, Turkey.
Isik Kaygusuz AtagunduzDepartment of Hematology, Marmara University School of Medicine, Istanbul, Turkey.
Marmara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrimary ocular adnexal lymphomas are cured by radiotherapy; however, complications are frequent and relapses may occur. In this case, we aimed to report the efficacy and safety of extended systemic rituximab (anti-CD 20 monoclonal antibody) therapy of conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.

methodsIn the standard regimen, rituximab is used as four consecutive weekly infusions of 375 mg/m

resultsDuring the examination of the sixth week, we observed partial response of the lesions in both eyes. At the end of the tenth cure, complete remission was achieved. No local or systemic adverse effect was observed. The patient has no signs of recurrence during the 22-months follow-up period.

conclusionExtended rituximab therapy may be an effective and well-tolerated first-line treatment option for bilateral conjunctival MALT lymphoma.

Indexed as

AdultBiopsyConjunctivaConjunctival NeoplasmsDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansImmunologic FactorsInfusions, IntravenousLymphoma, B-Cell, Marginal ZoneRituximabImmunologic FactorsRituximabAnti-CD20 monoclonal antibodyConjunctivaConjunctival MALT lymphomaExtranodal marginal zone lymphoma of mucosa-associated lymphoid tissue typeNon-Hodgkin lymphomaRituximab

Identifiers

PMID29411260
OpenAlexW2786811451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.